Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8ZHP1)

Drug Name
MCI-186 Drug Info
Synonyms
Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
Cross-matching ID
PubChem CID
4021
ChEBI ID
CHEMBL31530
CAS Number
CAS 89-25-8
TTD Drug ID
D06DLI
VARIDT Drug ID
DR00101
INTEDE Drug ID
DR1756
ACDINA Drug ID
D01030

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 1.86 9.13e-2 52/108 (48.15%) HEATR1;NOL6;GTPBP4;...
Endocrine and other factor-regulated calcium reabsorpti... 1.68 2.68e-1 49/53 (92.45%) GNAS;PRKCA;ATP1A1;...
Amoebiasis 1.66 2.13e-1 99/102 (97.06%) GNAS;PRKCA;LAMA3;...
Fructose and mannose metabolism 1.62 2.42e-1 30/33 (90.91%) PMM2;HK2;PFKP;...
Tyrosine metabolism 1.57 3.15e-1 30/36 (83.33%) ALDH3A1;ADH1B;ALDH3B1;...
Drug metabolism 1.56 2.80e-1 78/151 (51.66%) CES1;ALDH3A1;ADH1B;...
Aldosterone synthesis and secretion 1.56 2.46e-1 85/98 (86.73%) GNAS;PRKCA;ATP1A1;...
ECM-receptor interaction 1.56 2.21e-1 80/88 (90.91%) LAMA3;COL4A3;ITGA3;...
Morphine addiction 1.55 2.13e-1 80/91 (87.91%) GNAS;PRKCA;PDE4A;...
Serotonergic synapse 1.55 1.92e-1 97/114 (85.09%) GNAS;PRKCA;PLA2G4A;...
Focal adhesion 1.52 2.44e-1 180/201 (89.55%) PRKCA;LAMA3;COL4A3;...
Aldosterone-regulated sodium reabsorption 1.52 2.24e-1 34/37 (91.89%) PRKCA;ATP1A1;SGK1;...
Chagas disease 1.49 2.77e-1 93/102 (91.18%) GNAS;NFKBIA;C1QB;...
Gap junction 1.48 2.66e-1 72/88 (81.82%) GNAS;PRKCA;PDGFC;...
Long-term depression 1.46 2.86e-1 55/60 (91.67%) GNAS;PRKCA;PLA2G4A;...
Thyroid hormone synthesis 1.46 2.87e-1 66/75 (88%) GNAS;PRKCA;ATP1A1;...
Insulin secretion 1.45 2.77e-1 75/86 (87.21%) GNAS;PRKCA;ATP1A1;...
Glycolysis / Gluconeogenesis 1.45 2.65e-1 56/67 (83.58%) HK2;PFKP;ALDH3A1;...
Carbohydrate digestion and absorption 1.45 2.58e-1 37/47 (78.72%) HK2;ATP1A1;SLC37A4;...
Parathyroid hormone synthesis, secretion and action 1.42 2.92e-1 98/106 (92.45%) GNAS;PRKCA;PDE4A;...
HIF-1 signaling pathway 1.41 2.99e-1 105/109 (96.33%) PRKCA;HK2;MKNK2;...
Glutamatergic synapse 1.41 2.93e-1 97/114 (85.09%) GNAS;PRKCA;SLC1A1;...
Small cell lung cancer 1.37 3.66e-1 90/92 (97.83%) LAMA3;COL4A3;ITGA3;...
Pancreatic secretion 1.37 3.52e-1 87/102 (85.29%) GNAS;PRKCA;CPA3;...
GnRH secretion 1.37 3.46e-1 60/64 (93.75%) PRKCA;MAP2K1;PRKCB;...
Base excision repair 1.36 3.54e-1 29/33 (87.88%) FEN1;PARP2;POLD2;...
Neomycin, kanamycin and gentamicin biosynthesis 1.35 3.68e-1 5/5 (100%) HK2;HK3;GCK;...
Melanogenesis 1.35 3.61e-1 74/101 (73.27%) GNAS;PRKCA;DVL1;...
RNA transport 1.34 3.61e-1 128/186 (68.82%) NUP62;NUP85;EIF3B;...
Circadian rhythm 1.34 3.54e-1 26/31 (83.87%) BHLHE41;RORA;CUL1;...
NF-kappa B signaling pathway -1.29 3.31e-1 90/104 (86.54%) BIRC3;BIRC2;TRADD;...
African trypanosomiasis -1.30 3.33e-1 32/37 (86.49%) HBB;IDO1;SELE;...
TGF-beta signaling pathway -1.34 3.23e-1 81/94 (86.17%) TFDP1;INHBE;BMPR1B;...
Malaria -1.34 3.26e-1 44/50 (88%) CXCL8;ACKR1;SDC2;...
FoxO signaling pathway -1.36 3.24e-1 118/131 (90.08%) IL6;PCK1;CSNK1E;...
Wnt signaling pathway -1.37 3.08e-1 124/166 (74.7%) SENP2;MAP3K7;PRKACB;...
Folate biosynthesis -1.38 3.09e-1 23/26 (88.46%) TH;PAH;DHFR;...
Type I diabetes mellitus -1.39 2.86e-1 38/43 (88.37%) HLA-DPB1;HLA-DOB;HLA-G;...
Proteasome -1.39 2.96e-1 44/46 (95.65%) PSMB3;PSMD9;PSMC2;...
p53 signaling pathway -1.43 2.44e-1 63/73 (86.3%) CHEK2;BBC3;RCHY1;...
Basal cell carcinoma -1.44 2.23e-1 41/63 (65.08%) DDB2;FZD3;LEF1;...
Lipid and atherosclerosis -1.45 2.34e-1 190/215 (88.37%) PDPK1;APOB;HSPA1L;...
Cysteine and methionine metabolism -1.46 2.15e-1 43/50 (86%) MAT2B;GOT2;MDH2;...
Graft-versus-host disease -1.49 1.91e-1 32/42 (76.19%) PRF1;HLA-DQA1;HLA-DMB;...
Viral protein interaction with cytokine and cytokine re... -1.51 1.64e-1 84/100 (84%) CCR5;TNFRSF14;IL6;...
Legionellosis -1.51 1.70e-1 51/57 (89.47%) HSPA1L;RAB1A;CXCL1;...
Nicotinate and nicotinamide metabolism -1.55 1.23e-1 25/35 (71.43%) QPRT;NNT;NADK;...
Kaposi sarcoma-associated herpesvirus infection -1.57 1.18e-1 172/193 (89.12%) MAPK14;CCR5;JUN;...
Rheumatoid arthritis -1.57 1.25e-1 78/93 (83.87%) ATP6V0C;CXCL6;CTSL;...
Other glycan degradation -1.59 1.15e-1 13/18 (72.22%) AGA;MAN2C1;NEU1;...
Phagosome -1.60 1.13e-1 118/152 (77.63%) FCGR2A;CANX;THBS3;...
Epithelial cell signaling in Helicobacter pylori infect... -1.62 1.05e-1 62/70 (88.57%) ATP6V0C;JAM2;MAPK13;...
Biosynthesis of unsaturated fatty acids -1.63 1.12e-1 21/27 (77.78%) SCP2;ELOVL5;ELOVL2;...
Bladder cancer -1.65 1.01e-1 40/41 (97.56%) TYMP;FGFR3;CDKN2A;...
Collecting duct acid secretion -1.67 1.02e-1 22/27 (81.48%) ATP6V1B2;ATP6V0E2;ATP6V1G1;...
Antigen processing and presentation -1.69 9.98e-2 60/78 (76.92%) HLA-DQA1;HLA-DMB;CTSB;...
SNARE interactions in vesicular transport -1.69 1.12e-1 19/33 (57.58%) STX16;BET1;STX1A;...
Glycine, serine and threonine metabolism -1.70 1.37e-1 31/40 (77.5%) SRR;GAMT;CBS;...
Thiamine metabolism -1.74 1.31e-1 12/15 (80%) TPK1;AK1;AK4
Peroxisome -1.87 6.13e-2 72/82 (87.8%) PEX12;DAO;IDH1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 30uM 6H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 40uM 3H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H